Kestra Medical Technologies (KMTS) Stock Overview
Operates as a wearable medical device and digital healthcare company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KMTS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Kestra Medical Technologies, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.83 |
| 52 Week High | US$30.00 |
| 52 Week Low | US$14.10 |
| Beta | 0 |
| 1 Month Change | -13.13% |
| 3 Month Change | 4.63% |
| 1 Year Change | 48.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.53% |
Recent News & Updates
Recent updates
KMTS: Future Algorithm And Prescription Momentum May Support Undervalued Shares
Kestra Medical Technologies' analyst fair value estimate has moved from about $18.74 to $28.00, as analysts point to stronger revenue trends, improving prescription volumes, and supportive clinical and algorithm updates behind higher long term growth expectations, despite some caution on current valuation. Analyst Commentary Recent Street research on Kestra Medical Technologies highlights both optimism around revenue traction and a clear layer of caution.
KMTS: Revenue Momentum And Clinical Data Will Support Bullish 2027 Outlook
Kestra Medical Technologies' analyst price target has shifted from $30 to $32, as analysts point to stronger Assure prescription volume growth, broader account adoption, improved revenue cycle management, and updated clinical and algorithm data that support the revised fair value and model assumptions. What's in the News Kestra Medical Technologies reported Q4 fiscal 2026 revenue of US$28.6 million, with full year revenue rising 59% and Q4 revenue up 66%, while gross margin reached 54.8% as the rental model scaled.Wearable Cardiac Protection Tailwinds Will Drive Stronger Market Adoption Over The Next Decade
Catalysts About Kestra Medical Technologies Kestra Medical Technologies develops and rents wearable cardioverter defibrillator systems that help protect patients at risk of sudden cardiac arrest during cardiac recovery. What are the underlying business or industry changes driving this perspective?Cardiac Recovery Catalysts Will Shape Guideline Adoption And Margin Progress Over The Long Term
Catalysts About Kestra Medical Technologies Kestra Medical Technologies develops and rents wearable cardioverter defibrillator systems and related cardiac recovery solutions to protect patients at risk of sudden cardiac arrest outside the hospital. What are the underlying business or industry changes driving this perspective?Kestra Medical Systems: Momentum Has Returned
Summary Kestra Medical Technologies, Ltd. has rebounded with strong revenue growth and a raised full-year sales guidance, but margins remain a significant concern. KMTS shares trade at a premium valuation, now over 12x sales, following a 60% rally after a robust Q1 earnings report and guidance hike. Operating losses are accelerating, with cash burn only covered for about 1.5 years, driven by heavy sales and marketing investments. Despite commercial momentum, the risk-reward for KMTS is less attractive at current levels, so I remain cautious, with an intent to monitor the situation closely. Read the full article on Seeking AlphaIs Kestra Medical Technologies (NASDAQ:KMTS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Kestra Medical Technologies: A Potential Promising Public Offering
Summary Kestra Medical Technologies has seen rapid growth but incurs substantial operating losses, making its valuation exercise a hard one. The company's Cardiac Recovery System, including the ASSURE WCD, addresses a significant market need for sudden cardiac arrest intervention. Despite strong product adoption and a large addressable market, risks include high losses, being a one-product business, and potential growth slowdown. Given the mixed outlook, I am adopting a cautious wait-and-see approach, looking for more data on growth and operating leverage in upcoming quarters. Read the full article on Seeking AlphaShareholder Returns
| KMTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.4% | 3.9% | 0.8% |
| 1Y | 48.4% | -14.4% | 19.1% |
Return vs Industry: KMTS exceeded the US Medical Equipment industry which returned -14.2% over the past year.
Return vs Market: KMTS exceeded the US Market which returned 16.5% over the past year.
Price Volatility
| KMTS volatility | |
|---|---|
| KMTS Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KMTS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KMTS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 443 | Brian Webster | kestramedical.com |
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery.
Kestra Medical Technologies, Ltd. Fundamentals Summary
| KMTS fundamental statistics | |
|---|---|
| Market cap | US$1.36b |
| Earnings (TTM) | -US$131.61m |
| Revenue (TTM) | US$95.13m |
Is KMTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMTS income statement (TTM) | |
|---|---|
| Revenue | US$95.13m |
| Cost of Revenue | US$46.26m |
| Gross Profit | US$48.86m |
| Other Expenses | US$180.48m |
| Earnings | -US$131.61m |
Last Reported Earnings
Apr 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 51.37% |
| Net Profit Margin | -138.36% |
| Debt/Equity Ratio | 16.4% |
How did KMTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 09:36 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/04/30 |
| Annual Earnings | 2026/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kestra Medical Technologies, Ltd. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |